Press release
Globally, 5+ Key Companies are Actively Working in the Methylmalonic Academia Pipeline Landscape
Methylmalonic Academia Pipeline
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Download the sample pages:
https://www.delveinsight.com/report-store/methylmalonic-academia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Methylmalonic Academia Pipeline Analysis
The report provides insights into:
The report provides detailed insights about companies that are developing therapies in the Methylmalonic Academia Market.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Methylmalonic Academia treatment.
Methylmalonic Academia key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Methylmalonic Academia Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Methylmalonic Academia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for Sample PDF:
https://www.delveinsight.com/report-store/methylmalonic-academia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Methylmalonic Academia Therapeutics Analysis
There are approx. 5+ key companies developing Methylmalonic acidemia therapies. HemoShear Therapeutics has its drug candidates in the most advanced stage, i.e. Phase II of development.
Some of the key companies in the Methylmalonic Academia Market include:
• HemoShear Therapeutics
• LogicBio Therapeutics
• Moderna Therapeutics
• Selecta Biosciences
• PTC Therapeutics
• Poseida Therapeutics
And many others
Methylmalonic Academia Therapies covered in the report include:
• HST5040 (HemoShear Therapeutics)
• LB-001 (LogicBio Therapeutics)
And many more
DelveInsight's Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Request the Sample PDF to Get a more in-depth Assessment:
https://www.delveinsight.com/sample-request/methylmalonic-academia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Methylmalonic Academia Current Treatment Patterns
4. Methylmalonic Academia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Methylmalonic Academia Late Stage Products (Phase-III)
7. Methylmalonic Academia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Methylmalonic Academia Discontinued Products
13. Methylmalonic Academia Product Profiles
14. Methylmalonic Academia Key Companies
15. Methylmalonic Academia Key Products
16. Dormant and Discontinued Products
17. Methylmalonic Academia Unmet Needs
18. Methylmalonic Academia Future Perspectives
19. Methylmalonic Academia Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Request for the Sample PDF (to get a detailed understanding of the TOC, Tables, and Figures included in the report), at:
https://www.delveinsight.com/sample-request/methylmalonic-academia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/methylmalonic-academia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Globally, 5+ Key Companies are Actively Working in the Methylmalonic Academia Pipeline Landscape here
News-ID: 2696801 • Views: …
More Releases from DelveInsight Business Research
Global Advanced Melanoma Pipeline Accelerates With 60+ Emerging Therapies, Revea …
DelveInsight's "Advanced Melanoma Pipeline Insight 2025" report delivers an in-depth analysis of more than 55 companies and over 60 investigational therapies currently advancing through the Advanced Melanoma research landscape. It offers detailed profiles of both clinical- and preclinical-stage candidates and provides a thorough evaluation of therapies based on product type, development stage, route of administration, and molecule class. The report also outlines inactive or discontinued programs within this domain.
Explore the…
Global Spasticity Treatment Landscape Set for Transformation: DelveInsight Unvei …
DelveInsight's "Spasticity Pipeline Insight, 2025" report offers an in-depth evaluation of 10+ companies and more than 12 investigational therapies currently advancing through the Spasticity treatment pipeline. The report includes detailed profiles of clinical- and preclinical-stage candidates, along with a thorough assessment of therapies by product type, development phase, route of administration, and molecular class. It also highlights discontinued and inactive programs in the field.
Stay informed with the latest developments! Access…
Lewy Body Dementia Treatment Market 2034 - Market Size, Competitive Landscape, C …
The Lewy Body Dementia (LBD) market across the seven major markets (7MM) was valued at approximately USD 670 million in 2022, with strong growth anticipated through 2034. In 2022, an estimated 11 million dementia cases were recorded across the 7MM, of which ~0.6 million were attributed to Lewy Body Dementia. Rising disease prevalence-driven by aging demographics, enhanced diagnostic capabilities, and increasing awareness-is expected to stimulate market expansion. Companies including EIP…
Bronchitis Treatment Market 2034: Market Size, Competitive Landscape, Companies, …
The bronchitis therapeutics market is projected to grow steadily from 2025-2034, driven by rising disease prevalence, technological progress, and the emergence of new treatment options. Current management focuses on symptom relief through bronchodilators, corticosteroids, and antibiotics for acute cases, while chronic bronchitis requires long-term inhaled therapies, pulmonary rehabilitation, and lifestyle changes. A key advancement is the FDA-approved OHTUVAYRE (ensifentrine), which offers dual bronchodilator and anti-inflammatory benefits. Despite progress, there is…
More Releases for Methylmalonic
Methylmalonic Acidemia Market trends, Diagnosis, and Treatment Landscape
Methylmalonic Acidemia (MMA) is a rare inherited metabolic disorder resulting from defects in the metabolism of certain amino acids, cholesterol, and fatty acids. It is typically caused by mutations in genes responsible for the enzyme methylmalonyl-CoA mutase or related pathways. Patients with MMA are unable to properly break down specific compounds, leading to accumulation of toxic substances in the blood, which can result in developmental delays, recurrent metabolic crises, and…
Methylmalonic Acid Market: An In-Depth Analysis
In 2024, the market was valued at approximately USD 250 million and is projected to reach around USD 400 million by 2033, reflecting a compound annual growth rate (CAGR) of 5.5% from 2025 to 2033.
Methylmalonic Acid Market Overview
Methylmalonic acid serves as a crucial biomarker in clinical settings, aiding in the diagnosis of conditions such as methylmalonic acidemia and other vitamin B12-related disorders. The market's growth is fueled by the rising…
Methylmalonic Acidemia (MMA) Market Size Projected To Reach $12.5 Billion By 203 …
The Methylmalonic Acidemia (MMA) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Methylmalonic Acidemia (MMA) Market?
The market for methylmalonic acidemia (MMA) has experienced robust growth in the past few years. The size of the market is forecasted to…
Methylmalonic Acidemia Market 2023 Trends, Top Industry Players and Future Trend …
"According to the research report, the global methylmalonic acidemia market was valued at USD 9.16 billion in 2022 and is expected to reach USD 14.78 billion by 2032, to grow at a CAGR of 5.0% during the forecast period."
Get Sample with Latest Trends and Future Advancements @ https://www.polarismarketresearch.com/industry-analysis/methylmalonic-acidemia-market/request-for-sample
Polaris Market Research has recently published its latest analysis on Methylmalonic Acidemia Market 2023: By Types, Applications, Size, Share, Key Players & Regions…
Methylmalonic Acid Market Will Generate Record Revenue by 2029
The Methylmalonic Acid Market is anticipated to grow at a significant CAGR during the forecast period. Methylmalonic acid (MMA) is a substance created by the human body when it digests protein. The amount of vitamin B12 in the body controls the production of MMA in the body. A high amount of MMA typically means a deficiency of vitamin B12.?The major factor driving the growth of the market during the forecast…
Methylmalonic Acidemia Market to Show a Rise During the Forecast Period asserts …
DelveInsight's "Methylmalonic Acidemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Methylmalonic Acidemia, historical and forecasted epidemiology as well as the Methylmalonic Acidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Methylmalonic Acidemia market report provides current treatment practices, emerging drugs, Methylmalonic Acidemia market share of the individual therapies, and current and forecasted Methylmalonic Acidemia market size…
